Health Care • Biotechnology: Pharmaceutical Preparations
$11.04 ▼ -0.26
(-2.34%)
MKT CAP: $277.0M • VOL: 113.3K
52W L $7 52W H $45
ROARABLE / RQD
E • 30/100
PIOTROSKI
3 / 9
LYEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $36.0K | $61.0K | $130.0K |
| YoY Revenue Growth % | -41.0% | -53.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$269.4M | -$358.8M | -$247.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$274.4M | -$343.0M | -$234.6M |
| EBITDA (Normalized) | -$268.8M | -$358.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$150.0M | -$162.4M | -$163.7M |
| Capital Expenditures (CapEx) | $780.0K | $464.0K | — |
| Free Cash Flow (FCF) | -$150.8M | -$162.9M | -$163.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $60.2M | $105.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $248.2M | $382.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LYEL.